Filing Details

Accession Number:
0001144204-10-025914
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-05-10 13:00:00
Reporting Period:
2010-05-06
Filing Date:
2010-05-10
Accepted Time:
2010-05-10 18:55:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
946840 Viropharma Inc VPHM Pharmaceutical Preparations (2834) 232789550
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1087939 Julian Baker 667 Madison Avenue, 17Th Floor
New York NY US 10021
No No Yes No
1087940 Felix Baker 667 Madison Avenue, 17Th Floor
New York NY US 10021
No No Yes No
1244389 Baker Biotech Capital (Gp), Llc 667 Madison Avenue, 17Th Floor
New York NY US 10021
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-05-06 224,106 $12.65 2,911,693 No 4 S Indirect Through Partnership
Common Stock Disposition 2010-05-06 62,658 $12.62 2,849,035 No 4 S Indirect Through Partnership
Common Stock Disposition 2010-05-07 97,940 $12.46 2,751,095 No 4 S Indirect Through Partnership
Common Stock Disposition 2010-05-10 463,082 $12.70 2,288,013 No 4 S Indirect Through Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Through Partnership
No 4 S Indirect Through Partnership
No 4 S Indirect Through Partnership
No 4 S Indirect Through Partnership
Footnotes
  1. In addition to Baker Biotech Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Biotech Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were members of a group of such shareholders. (Continued in footnote 2).
  2. However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
  3. Represents securities owned directly by 667, L.P., the sole general partner of which is Baker Biotech Capital, L.P., a limited partnership the sole general partner of which is Baker Biotech Capital (GP),LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Biotech Capital (GP), LLC.